Septerna SVP sells 15K shares, exercises options
Septerna, Inc. SVP of Drug Discovery Daniel D. Long reported option exercises and share sales in SEPN stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Septerna, Inc. SVP of Drug Discovery Daniel D. Long reported option exercises and share sales in SEPN stock. On June 22, 2026, he exercised options for 4,471 shares at $11.70 per share and 10,529 shares at $2.76 per share, converting them into common stock.
On the same date, he sold 7,000 shares at a weighted average price of $35.9687 and 8,000 shares at $35.1001 in open-market transactions under a pre-arranged Rule 10b5-1 sales plan. After these transactions, he directly holds 96,412 shares of common stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 15,000 shares ($451K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Long Daniel D.
Role
SVP, Drug Discovery
Sold
15,000 shs ($533K)
Approx. gross sale proceeds
$533K
Approx. exercise cost
$81K
Approx. pre-tax spread
$451K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,529 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 4,471 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,529 | $2.76 | $29K |
| Exercise | Common Stock | 4,471 | $11.70 | $52K |
| Sale | Common Stock | 8,000 | $35.1001 | $281K |
| Sale | Common Stock | 7,000 | $35.9687 | $252K |
Holdings After Transaction:
Stock Option (Right to Buy) — 35,905 contracts (Direct);
Common Stock — 96,412 shares (Direct)
Footnotes (6)
- F1. Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on April 30, 2026 in a transaction that was exempt under Rule 16b-3(c).
- F2. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.70 to $35.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.71 to $36.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F6. 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Shares sold: 15,000 shares
First sale price: $35.9687/share
Second sale price: $35.1001/share
+5 more
8 metrics
Shares sold
15,000 shares
Common stock sold in open-market transactions on June 22, 2026
First sale price
$35.9687/share
7,000 common shares sold at weighted average price
Second sale price
$35.1001/share
8,000 common shares sold at weighted average price
Options exercised at $11.70
4,471 shares
Common stock acquired via option exercise
Options exercised at $2.76
10,529 shares
Common stock acquired via option exercise
Shares held after transactions
96,412 shares
Direct ownership of Septerna common stock after June 22, 2026
ESPP shares acquired
3,501 shares
Acquired April 30, 2026 under 2024 Employee Stock Purchase Plan
10b5-1 plan adoption date
March 20, 2026
Pre-arranged sales plan governing reported stock sales
Key Terms
Rule 10b5-1, weighted average price, Employee Stock Purchase Plan, Rule 16b-3(c), +2 more
6 terms
Rule 10b5-1 regulatory
"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026."
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average price financial
"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.70 to $35.64."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Purchase Plan financial
"Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on April 30, 2026 in a transaction that was exempt under Rule 16b-3(c)."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Rule 16b-3(c) regulatory
"Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on April 30, 2026 in a transaction that was exempt under Rule 16b-3(c)."
An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 4,471 shares and a $11.7000 conversion or exercise price."
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion" for option transactions converting into common stock."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Septerna (SEPN) SVP Daniel Long report?
Daniel D. Long reported both option exercises and share sales. He exercised options for 15,000 Septerna common shares, then sold 15,000 shares in open-market trades, while continuing to hold 96,412 shares directly after the transactions.
What stock options did the Septerna (SEPN) SVP exercise in this filing?
He exercised options covering 4,471 Septerna shares at a $11.70 exercise price and 10,529 shares at a $2.76 exercise price. These option exercises converted derivative positions into common stock before the related share sales.
Were the Septerna (SEPN) insider sales made under a Rule 10b5-1 plan?
Yes. A footnote states the sales were effected pursuant to a Rule 10b5-1 sales plan adopted by Daniel D. Long on March 20, 2026, indicating the trades were pre-arranged rather than timed discretionarily.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates